Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06610201 · ClinicalTrials.gov registry record

A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

A clinical trial of Von Willebrand Disease (VWD) and Von Willebrand Disease (VWD), Type 1, sponsored by Hemab ApS.

Recruiting
Registry status
200
Enrollment target
17
Study locations

NCT06610201 is a study of Von Willebrand Disease (VWD) and Von Willebrand Disease (VWD), Type 1 that is actively recruiting participants, run by Hemab ApS. The registered enrollment target is 200 participants, above the 59-participant average among 4 other Von Willebrand Disease (VWD) trials with a reported enrollment target (239% higher). The trial reports 17 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06610201, a study of Von Willebrand Disease (VWD) and Von Willebrand Disease (VWD), Type 1, is actively recruiting participants, sponsored by Hemab ApS.

RECRUITING
Registry status
200 participants
Enrollment target
17
Study locations

Study Summary

The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a population of participants with VWD and act as comparator data for future clinical study outcomes.(e.g. Velora Pioneer)

Conditions Studied

Von Willebrand Disease (VWD) Von Willebrand Disease (VWD), Type 1 Von Willebrand Disease (VWD), Type 2 Von Willebrand Disease (VWD), Type 3 Von Willebrand Disease, Type 2A Von Willebrand Disease, Type 2M Von Willebrand Disease, Type 2N

Interventions

  • OTHER Clinical outcomes of patients with VWD, Type 1
  • OTHER Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3

Study Locations (17)

Arizona

  • Phoenix Children's Hospital - Phoenix

Arkansas

  • Arkansas Children's Hospital - Little Rock

California

  • Children's Hospital of Los Angeles - Los Angeles

Florida

  • University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center - Miami

Georgia

  • Emory Children's Center - Atlanta

Indiana

  • Innovative Hematology, Inc./Indiana Hemophilia and Thrombosis Center - Indianapolis

Louisiana

  • Tulane University School of Medicine - New Orleans

Michigan

  • University of Michigan Hospitals, Department of Hemophilia and Coagulation Disorders - Ann Arbor

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-08-30
Est. Completion 2026-06

Sponsor

Hemab ApS

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06610201

The ClinicalTrials.gov registry entry for NCT06610201 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 59-participant average among 4 other Von Willebrand Disease (VWD) trials with a reported enrollment target (239% higher). The listed sponsor is Hemab ApS, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Von Willebrand Disease (VWD) appearing as the primary indexed condition, and to 2 interventions - of which Clinical outcomes of patients with VWD, Type 1 is the first listed.

NCT06610201 reports 17 study locations spanning 17 distinct geographic areas - top geographies include Arizona, Arkansas, California.

Frequently Asked Questions

What is clinical trial NCT06610201 about?

NCT06610201 is a clinical study titled "A Study of Bleeding and Treatment in Participants With Von Willebrand Disease". The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a popul...

What is the current status of trial NCT06610201?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2024-08-30. Estimated completion is 2026-06.

What conditions does trial NCT06610201 study?

This clinical trial studies the following conditions: Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3, Von Willebrand Disease, Type 2A.

What interventions are being tested in trial NCT06610201?

The interventions under investigation include: Clinical outcomes of patients with VWD, Type 1 (OTHER), Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3 (OTHER).

Who is sponsoring clinical trial NCT06610201?

This trial is sponsored by Hemab ApS, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06610201 being conducted?

This trial has 17 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Von Willebrand Disease (VWD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Von Willebrand Disease (VWD)

All registered trials for this condition

Von Willebrand Disease (VWD), Type 1

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.